NK-3 receptor antagonism prevents behavioral sensitization to cocaine: a role of glycogen synthase kinase-3 in the nucleus accumbens

被引:8
|
作者
Nwaneshiudu, Chinwe A. [1 ,2 ]
Unterwald, Ellen M. [1 ,2 ,3 ]
机构
[1] Temple Univ, Dept Pharmacol, Sch Med, Philadelphia, PA 19140 USA
[2] Temple Univ, Ctr Subst Abuse Res, Sch Med, Philadelphia, PA 19140 USA
[3] Rockefeller Univ, Lab Biol Addict Dis, New York, NY 10021 USA
基金
美国国家卫生研究院;
关键词
cocaine; dopamine; GSK3; nucleus accumbens; NK-3R; sensitization; MESSENGER-RNA EXPRESSION; ELEMENT-BINDING PROTEIN; CENTRAL-NERVOUS-SYSTEM; NEUROKININ-B; AGONIST SENKTIDE; GENE-EXPRESSION; MOTOR-ACTIVITY; DOPAMINE; RAT; NEURONS;
D O I
10.1111/j.1471-4159.2010.06973.x
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
P>Repeated administration of cocaine induces heightened behavioral hyperactivity termed sensitization. Although NK-3 receptors have been shown to modulate acute cocaine-induced behaviors, their role in behavioral sensitization is unknown. The present study investigated whether NK-3 receptor blockade altered behavioral sensitization to cocaine. Additionally, glycogen synthase kinase-3 (GSK3) has been shown to be involved in dopamine receptor signaling and in development of sensitization; therefore regulation of GSK3 activity in the nucleus accumbens was also investigated. Administration of the NK-3 receptor antagonist SB 222200 (5 mg/kg, s.c.) prior to repeated cocaine (20 mg/kg, i.p.) prevented the development of sensitized responses after a cocaine challenge. Pre-treatment with SB 222200 before a cocaine challenge also blocked expression of sensitization. Decrease in GSK3 activity demonstrated by increased phosphorylation of GSK3 alpha and GSK3 beta was detected 20 mins after an acute cocaine injection. In contrast, a cocaine challenge failed to alter phosphorylation of GSK3 alpha and GSK3 beta in sensitized mice. SB 222200 prior to repeated cocaine resulted in increased phosphorylation of GSK3 alpha and GSK3 beta akin to changes following acute cocaine. Collectively, these findings demonstrate the involvement of NK-3 receptors in development and expression of behavioral sensitization and in regulation of GSK3 activity in the nucleus accumbens after repeated cocaine.
引用
收藏
页码:635 / 642
页数:8
相关论文
共 50 条
  • [41] QSAR modeling of the inhibition of Glycogen Synthase Kinase-3
    Katritzky, Alan R.
    Pacureanu, Liliana M.
    Dobchev, Dimitar A.
    Fara, Dan C.
    Duchowicz, Pablo R.
    Karelson, Mati
    BIOORGANIC & MEDICINAL CHEMISTRY, 2006, 14 (14) : 4987 - 5002
  • [42] Glycogen synthase kinase-3 a negative regulator of hypertrophy
    Haq, SE
    Choukroun, G
    Lee, KH
    Ranu, H
    Vayssier-Taussat, M
    Boecker, W
    Woodgett, J
    Molkentin, JD
    Michael, A
    Force, T
    CIRCULATION, 2000, 102 (18) : 140 - 140
  • [43] Glycogen synthase kinase-3: A potential target for diabetes
    Teli, Divya M.
    Gajjar, Anuradha K.
    BIOORGANIC & MEDICINAL CHEMISTRY, 2023, 92
  • [44] Glycogen Synthase Kinase-3β in Ischemic Neuronal Death
    Hanumanthappa, Pradeep
    Densi, Asha
    Krishnamurthy, Rajanikant Golgodu
    CURRENT NEUROVASCULAR RESEARCH, 2014, 11 (03) : 271 - 278
  • [45] Presenilin 1 regulation of glycogen synthase kinase-3β
    Vestling, M
    Cowburn, RF
    Lovestone, S
    NEUROBIOLOGY OF AGING, 2002, 23 (01) : S517 - S517
  • [46] Glycogen synthase kinase-3β, mood stabilizers, and neuroprotection
    Li, XH
    Bijur, GN
    Jope, RS
    BIPOLAR DISORDERS, 2002, 4 (02) : 137 - 144
  • [47] Regulation of glycogen synthase kinase-3 by hexosamines.
    Crook, ED
    Singh, L
    DIABETES, 1996, 45 : 348 - 348
  • [48] Glycogen Synthase Kinase-3 and Leukemia: Restoring the Balance
    Birch, Noah W.
    Zeleznik-Le, Nancy J.
    CANCER CELL, 2010, 17 (06) : 529 - 531
  • [49] Targeting glycogen synthase kinase-3 in insulin signalling
    Frame, Sheelagh
    Zheleva, Daniella
    EXPERT OPINION ON THERAPEUTIC TARGETS, 2006, 10 (03) : 429 - 444
  • [50] Hyperactivity: Glycogen synthase kinase-3 as a therapeutic target
    Mines, Marjelo A.
    EUROPEAN JOURNAL OF PHARMACOLOGY, 2013, 708 (1-3) : 56 - 59